These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26667309)

  • 21. [Development of polymeric nanoparticles-based vaccine].
    Akagi T; Akashi M
    Nihon Rinsho; 2006 Feb; 64(2):279-85. PubMed ID: 16454182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.
    Gnopo YMD; Watkins HC; Stevenson TC; DeLisa MP; Putnam D
    Adv Drug Deliv Rev; 2017 May; 114():132-142. PubMed ID: 28501509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulatory biomaterials.
    Mallapragada SK; Narasimhan B
    Int J Pharm; 2008 Dec; 364(2):265-71. PubMed ID: 18662761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery systems for molecular vaccination.
    Sheikh NA; al-Shamisi M; Morrow WJ
    Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.
    Jones SD
    IDrugs; 2010 Oct; 13(10):692-4. PubMed ID: 20878589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems.
    Friede M; Aguado MT
    Adv Drug Deliv Rev; 2005 Jan; 57(3):325-31. PubMed ID: 15560944
    [No Abstract]   [Full Text] [Related]  

  • 30. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
    van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
    Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salmonella enterica as a vaccine carrier.
    Hegazy WA; Hensel M
    Future Microbiol; 2012 Jan; 7(1):111-27. PubMed ID: 22191450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases.
    Bolhassani A; Javanzad S; Saleh T; Hashemi M; Aghasadeghi MR; Sadat SM
    Hum Vaccin Immunother; 2014; 10(2):321-32. PubMed ID: 24128651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoengineering of vaccines using natural polysaccharides.
    Cordeiro AS; Alonso MJ; de la Fuente M
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1279-93. PubMed ID: 26049133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The path to a successful vaccine adjuvant--'the long and winding road'.
    O'Hagan DT; De Gregorio E
    Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasal vaccine innovation.
    Jabbal-Gill I
    J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-Assembled Nanoparticles: Exciting Platforms for Vaccination.
    Pan J; Cui Z
    Biotechnol J; 2020 Dec; 15(12):e2000087. PubMed ID: 33411412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-based self-adjuvanting vaccines.
    Brown LE; Jackson DC
    Curr Drug Deliv; 2005 Oct; 2(4):383-93. PubMed ID: 16305441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-protamine-DNA-mediated antigen delivery.
    Vangasseri DP; Han SJ; Huang L
    Curr Drug Deliv; 2005 Oct; 2(4):401-6. PubMed ID: 16305443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.